Home Trials Genes Drugs 23andMe Graph Blog Contact

Home
Trials
Genes
Drugs
23andMe
Graph
Blog
Contact

Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

ClinicalTrials.gov
OpenTargets
ClinVar
PubChem

Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients

N/ATerminatedNCT00241462

AstraZeneca150 enrolled

Overview

The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal * Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status * Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment Exclusion Criteria: * Life threatening metastases

Locations (43)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Alkmaar, Netherlands

Research Site

Almelo, Netherlands

Research Site

Almere Stad, Netherlands

Research Site

Amsterdam, Netherlands

Research Site

Apeldoorn, Netherlands

Research Site

Assen, Netherlands

Research Site

Bergen op Zoom, Netherlands

Research Site

Capelle aan den IJssel, Netherlands

Research Site

Delft, Netherlands

Research Site

Delfzijl, Netherlands

...and 33 more locations